tirzepatide trial reduces albuminuria among adults with type 2 diabetes in SURPASS trials Weight-loss jab Mounjaro trial begins

"Some can maintain on a lower dose, while others require ongoing therapy at their current dose." If you're like me and squeamish about the prospect of weekly injections indefinitely, take note that oral GLP-1s are now on the market: the Food and Drug Administration (FDA) approved oral Wegovy in December 2025 and Foundayo (orforglipron) in April 2026

C., Tadayon, S., Vergs, B., & Marre, M

If you have PCOS and a BMI of 27+ with a weight-related condition (such as diabetes or high cholesterol), or a BMI of 30 or higher, you may be eligible for a Mounjaro prescription

On the flip side, recent studies show that GLP-1 medications may decrease a persons risk for cardiovascular disease and dementia

We conduct several quality assurance tests on our products and are an excellent pharmaceutical institution overall

US-licensed 503A compounding pharmacy When prescribed, GHK-Cu is compounded for the individual patient at a US-licensed pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act